Hepatocellular Cancer: Molecular Mechanisms, Diagnosis and Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1655
Special Issue Editor
Special Issue Information
Dear Colleagues,
Liver cancer is a devastating disease with poor prognosis. Approximately 80% of HCCs arise in patients with a background of long-lasting chronic liver disease. In order to understand the pathogenesis of HCC, therefore, it is important to know what is happening in the chronically diseased liver. The regenerating liver is an ambient setting full of inflammation, stress and signal/cell interactions: a vivid and complex substrate in which HCCs arise.
Primary liver cancers are traditionally classified into hepatocellular carcinoma (HCC) and the less common but more aggressive cholangiocarcinoma (CCA), a cancer with cholangiocyte (also known as biliary epithelial cell, BEC) characteristics. A major obstacle in treating primary liver cancers is their enormous heterogeneity, forming a spectrum from pure HCC, through mixed and intermediate tumours, to pure CCA; the more cholangiocytic their characteristics, the more aggressive they are. During progression and in response to treatment, primary liver cancers can adapt and become resistant to treatment, often with an amplified cholangiocytic character. How HCC cells acquire cellular plasticity and how they shift phenotype is not known. Understanding these mechanisms is important because this will direct approaches to suppress the evolution of liver cancer into more aggressive forms.
In this Special Issue we would like to focus on the pathogenesis of hepatocellular cancer at the cellular and molecular levels, on the diagnosis and classification of liver cancer, and on potential treatment options.
Prof. Dr. Tania Roskams
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- primary liver cancer
- liver cancer pathogenesis
- liver cancer classification
- liver cancer diagnosis
- liver cancer treatment
